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Introduction.Weevaluated the effects of a therapy that combinesmyo-inositol (MI) andD-chiro-inositol (DCI) in young overweight
women affected by polycystic ovary syndrome (PCOS), characterized by oligo- or anovulation and hyperandrogenism, correlated
to insulin resistance. Methods. We enrolled 46 patients affected by PCOS and, randomly, we assigned them to two groups, A and
B, treated, respectively, with the association of MI plus DCI, in a 40 : 1 ratio, or with placebo (folic acid) for six months. Thus,
we analyzed pretreatment and posttreatment FSH, LH, 17-beta-Estradiol, Sex Hormone Binding Globulin, androstenedione, free
testosterone, dehydroepiandrosterone sulphate, HOMA index, and fasting glucose and insulin. Results.We recorded a statistically
significant reduction of LH, free testosterone, fasting insulin, andHOMA index only in the group treatedwith the combined therapy
of MI plus DCI; in the same patients, we observed a statistically significant increase of 17-beta-Estradiol levels. Conclusions. The
combined therapy of MI plus DCI is effective in improving endocrine and metabolic parameters in young obese PCOS affected
women.
1. Introduction
Polycystic ovary syndrome (PCOS) is a heterogeneous syn-
drome, involving a growing number of women in repro-
ductive age, diagnosed on the basis of three different fac-
tors: oligo- or anovulation, clinical/biochemical hyperandro-
genism, and polycystic ovary, with the presence on ultra-
sound of ≥12 follicles in each ovary measuring 2 ± 9mm
in diameter and/or increased ovarian volume (>10mL) [1,
2]. PCOS affected patients that had menstrual irregularity,
followed in many cases by infertility [3, 4] and mood
disorders, such as anxiety and depression [5]. Though PCOS
pathogenesis still remains unclear, insulin resistance (IR) and
the consequential hyperinsulinemia are considered primary
triggers, both in obese and in leanwomenwith this syndrome
[6–8]. Indeed, hyperinsulinemia induced by IR occurs in
roughly 80% of PCOS obese women, as in 30–40% of PCOS
lean women [9], suggesting that IR is independent but also
exacerbated by obesity; this latter considered an enhanc-
ing factor that positively correlates with the multifactorial
syndrome [10–12]. It was hypothesized that in patients with
PCOS altered insulin signaling may generate the IR which
in turn causes abnormal ovarian steroidogenesis [13, 14],
so that several insulin-sensitizing compounds have been
proposed as possibly safe and efficacious long-term treatment
of PCOS [15]. Among these drugs, metformin resulted to
be the most used and studied drug, even if this molecule is
predominantly associated with gastrointestinal discomforts
consisting of bloating, nausea, and diarrhea [14, 16]. Inter-
esting and promising results have been obtained focusing on
two inositol stereoisomers, such as myo-inositol (MI) and D-
chiro-inositol (DCI), acting like insulinmediators [17–19]. As
insulin secondmessengers, both thesemolecules are involved
in increasing insulin sensitivity of different tissues to improve
metabolic and ovulatory functions [20]. In particular, at
low dosage, DCI restores normal insulin sensitivity in the
typical insulin target tissues, reducing the circulating insulin
and androgens and inducing an enhancement in ovulation
frequency. On the contrary, MI exerts its beneficial effects
mainly at the ovary level, where it is highly concentrated,
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both enhancing insulin pattern and also directly acting on a
number of ovarian functions, including steroidogenesis [21].
Some authors [22] postulated that PCOS affected women,
with IR, presenting in the ovary a misbalance in MI/DCI
ratio, resulting in DCI overproduction and in turn in a
deficiency inMI,whichwould explain the excessive androgen
biosynthesis. Other authors [23], instead, proposed that the
increased androgen levels in PCOS patients might be linked
to a decreased MI/DCI. In a recent study, Facchinetti et
al. [24] discovered that the physiological MI/DCI ratio was
40 : 1 and, based on this finding, as well as on the specific
behavior of both stereoisomers, we investigated the effects of
a therapy that combines MI plus DCI in the ratio of 40 : 1,
versus placebo, in order to improve some clinical outcomes
in PCOS young overweight women.
2. Methods
2.1. Patients and Study Design. This randomized controlled
trial enrolled 46 obese women with BMI > 30 who were
affected by PCOS according to Rotterdam criteria [1, 2].
All the women were enrolled at the Department of Clinical
and Experimental Medicine, University of Pisa. Patients with
diabetes, smokers, and alcohol users were ruled out from the
study. After all patients subscribed their written informed
consent to be involved into the study, they were randomly
assigned to two groups, A and B. At baseline, patients in
groups A and B did not differ significantly. In group A, 21
women received MI plus DCI combined treatment at the
ratio of 40 : 1 (the physiologic ratio of the two isomers in the
body) in soft gel capsule containing 550mg of MI, 13.8mg
of DCI, and 200𝜇g of folic acid (INOFOLIC COMBI,
LO.LI.PHARMA) twice a day. Group B, with 25 women,
received the same amount of folic acid (200𝜇g) as placebo
twice a day. The treatments were performed for six months.
At the beginning of the study, all the patients were in the
follicular phase of the menstrual cycle.
2.2. Study Measurements. All patients were evaluated for
FSH, LH, 17-beta-Estradiol (E), Sex Hormone Binding Glob-
ulin (SHBG), androstenedione, free testosterone, and dehy-
droepiandrosterone sulphate (DHEAS) levels at the baseline
and after the sixmonths of therapy withMI plus DCI associa-
tion or with placebo. FSH and LH serum levels were detected
by immune-enzymatic assay (Access Immunoassay System,
hLH, hFSH, Beckman Coulter, Brea, CA, USA). Estradiol
levels were measured by competitive immunoassay (Access
Immunoassay System, Estradiol, BeckmanCoulter, Brea, CA,
USA). SHBG levels were detected by immunoassay (Access
Immunoassay System, SHBG, Beckman Coulter, Brea, CA,
USA). Serum levels of androstenedione were measured by
conventional immune-enzymatic assay (Access Immunoas-
say System, androstenedione, Beckman Coulter, Brea, CA,
USA). Free testosterone serum levels were measured by
immune-enzymatic assay (Access Immunoassay System, free
testosterone, Beckman Coulter, Brea, CA, USA). DHEASwas
measured by conventional immunoassay (Access Immunoas-
say System, DHEAS, Beckman Coulter, Brea, CA, USA).
Table 1: Characteristics of patients who received MI plus DCI
(group A) or placebo treatment (group B).
Group A (𝑛 = 21) Group B (𝑛 = 25)
Age (years) 23 ± 6.8 25 ± 7.3
Height (cm) 164 ± 6.7 168 ± 6.9
Weight (kg) 85 ± 13.5 88 ± 14
BMI 32 ± 4.8 31 ± 4.6
BMI: body mass index.
Insulin resistance was measured by means of Homeostasis
Model Assessment (HOMA) in addition to determining
fasting glucose and insulin with the same timeline and
modalities. Blood samples, taken at the baseline and after the
six-month treatment period under similar conditions, were
separated by centrifugation at 2000×g for 15 minutes at 4∘C,
and the serum obtained was stored at −20∘C within one hour
of collection. Before the analysis, all the serum samples were
thawed and entirely mixed.
2.3. Statistical Analysis. Data reported indicatemean values±
standard deviation (SD). Paired 𝑡-test was used to identify the
differences between variables at baseline and after six months
of treatment with MI plus DCI or with placebo, respectively.
Differences were considered statistically significant at 𝑝 value
<0.05.
3. Results and Discussion
The goal of this study was to investigate if the therapy
combiningMI andDCI in the ratio of 40 : 1 could improve the
endocrine profile and the insulin resistance of obese women
with a PCOS diagnosis. To address this issue, 46 young obese
patients affected by this syndrome, whose characteristics
are summarized in Table 1, were randomly included in two
groups and then treated withMI plus DCI at the ratio of 40 : 1
with or placebo for six months. Insulin resistance, evaluated
as HOMA index, fasting insulin, and fasting glucose, and
also hormonal parameters were determined at the baseline
and after the six-month therapy. As shown in Table 2, we
observed that, with respect to the baseline values, only the
combined therapy of MI plus DCI significantly rebalanced
the endocrine and metabolic profiles of these patients, ame-
liorating their insulin resistance and the ovulatory func-
tion, as successfully recorded by ultrasound. As a matter
of fact, LH and free testosterone levels decreased after the
combined treatment, downregulating the hyperandrogenism,
and even HOMA index and fasting insulin, markers of
insulin resistance, resulted to be significantly reduced. On
the other hand, E and SHBG significantly increased, showing
restoring in ovulation capability. No relevant changes in
these sex hormones were reported in group B, treated with
placebo, and no significant modifications were observed after
the treatment in both groups A and B for what concerns
BMI, FSH, androstenedione, DHEAS, and fasting glucose.
Importantly, no relevant side effect was recorded during the
combined therapy with MI plus DCI. Overall, these results
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Table 2: Baseline and posttreatment endocrine and metabolic parameters of groups A and B of PCOS patients.
Group A (𝑛 = 21) Group B (𝑛 = 25)
Baseline MI plus DCI p value Baseline placebo 𝑝 value
FSH (mIU/mL) 5.86 ± 1.75 4.96 ± 1.74 ns 5.67 ± 1.11 5.47 ± 0.63 ns
LH (mIU/mL) 12.5 ± 8 8.5 ± 4.04 𝑝 < 0.05 11.27 ± 7.2 11.25 ± 5.35 ns
E (pg/mL) 47.06 ± 18.20 107.42 ± 92.86 𝑝 < 0.01 50.37 ± 19.45 52 ± 20.2 ns
Fasting insulin (𝜇U/mL) 20.19 ± 8.14 10.74 ± 5.46 𝑝 < 0.001 18 ± 8 17.8 ± 8.2 ns
Fasting glucose (mg/dL) 85 ± 5.96 86 ± 7.12 ns 86.2 ± 9.1 84.73 ± 8.3 ns
Free testosterone (ng/dL) 0.76 ± 0.20 0.62 ± 0.15 𝑝 < 0.05 0.85 ± 0.22 0.83 ± 0.2 ns
SHBG (nmol/L) 24.11 ± 10.35 35.85 ± 24.3 𝑝 < 0.05 20.44 ± 8.77 21.36 ± 7.57 ns
Androstenedione (ng/mL) 4.25 ± 1.48 4.01 ± 1.70 ns 3.48 ± 1.21 3.12 ± 2.23 ns
DHEAS (𝜇g/dL) 327.32 ± 150.89 347.6 ± 170.98 ns 337.95 ± 155.79 315.83 ± 145.59 ns
HOMA 3.38 ± 1.97 1.97 ± 1.48 𝑝 < 0.05 3.48 ± 2.02 2.8 ± 1.4 ns
E, 17-beta-Estradiol; P, progesterone; 17OHP, 17-OH-progesterone; SHBG, Sex Hormone Binding Globulin; DHEAS, dehydroepiandrosterone sulphate.
demonstrated the clinical importance of a combined therapy
ofMI plus DCI to correct the PCOSmetabolic and reproduc-
tive aspects and they are largely in agreement with the issues
discussed on the two international consensus conferences
on MI, DCI, and their link with PCOS [25, 26]. PCOS is a
syndrome whose pathogenesis remains still largely unclear,
even though several etiological factors are demonstrated to
be involved. Compelling evidences claimed the pivotal role of
insulin resistance and/or compensatory hyperinsulinemia in
this syndrome [9, 27–29]; indeed they tightly contribute both
directly (increasing the ovarian production of androgens)
and indirectly (modulating the hepatic SHBG synthesis) to
hyperandrogenism development, one of the main features of
those patients affected by PCOS [30, 31], especially in case
of overweight women [32]. Nevertheless, literature findings
consistently demonstrated that a deficiency in the tissue avail-
ability and/or usage of MI and/or DCI in women diagnosed
with PCOS could likely concur to the IR typical of this
syndrome [22, 23]. The two inositol stereoisomers, MI and
DCI, acting as insulin-sensitizers, have been demonstrated
to positively influence the clinical history of PCOS patients,
ameliorating their endocrine and metabolic profile both
alone and in combination [19, 33–37]. DCI alone, at low
dosage, may restore normal insulin sensitivity in the typical
insulin target tissues, inducing an enhancement in ovulation
frequency which could be ascribed to the general improved
insulin sensitivity and to the reduced circulating insulin and
androgens. On the contrary, MI exerts its beneficial effects
mainly at the ovary level, both enhancing insulin pattern
and also directly acting on a number of ovarian functions,
including steroidogenesis [22]. The ability of both inositol
stereoisomers to regulate glucose metabolism in a different
manner (DCI promotes glycogen synthesis, while MI may
support glucose cell intake) [38] is mirrored by their different
concentration in the tissues: whileDCI is highly concentrated
in glycogen storage tissues (liver, muscles, and fat), MI is
more abundant in those tissues that need a large amount
of glucose, such as brain, heart, or ovary [39]. From this
knowledge, a combined therapy with MI plus DCI in their
physiological plasma ratio (MI/DCI 40 : 1) seems to be the
most appropriated clinical approach to integrate the positive
effects exerted by both inositol stereoisomers.
4. Conclusions
The data reported are encouraging and they offer therapeutic
options to the first-line treatments in PCOS women with
moderate or severe hyperandrogenism and/or menstrual
abnormalities, which are represented by metformin as well as
by oral contraceptives.These compounds effectively suppress
LH release and the consequent androgen production from the
ovary; also they increase the sex hormone binding protein
synthesis, lowering the levels of circulating free androgens
[40]. Unfortunately, if the patient aims to restore ovulation in
order to conceive, contraceptives are not the clinical strategy
to follow. Furthermore, prolonged use of contraceptives may
increase homocysteine levels after six months of treatment
[41], as well as the risk of venous thromboembolism [42].
For what concerns metformin, several side gastrointestinal
effects (diarrhoea, nausea, vomiting, and abdominal bloat-
ing) and metabolic complications have been evidenced after
a long-term treatment [43]. For all these reasons, even
though more studies on a higher number of patients and
with greater statistical significance are needed to confirm
these striking posttreatment outcomes, safe combined use of
inositol stereoisomers should be largely suitable and it might
represent a valid clinical approach in PCOS management.
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